Annals of Surgical Treatment and Research

  • 제77권1호
  • /
  • Pages.29-36
  • /
  • 2009
  • /
  • 2288-6575(pISSN)
  • /
  • 2288-6796(eISSN)
대한외과학회 (The Korean Surgical Society)
권호 표지
DOI QR코드

DOI QR Code

갑상선유두암에서 Galectin-3, p53, Ki-67 단백질의 발현과 임상학적 의미

Clinical Significance of p53, Ki-67 and Galectin-3 Expressions in Papillary Thyroid Carcinoma

김병섭;강경호;임영아;김이수
Kim, Byung-Seup;Kang, Kyung-Ho;Lim, Young-Ah;Kim, Lee-Su

  • 발행 : 20090700
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: There are few molecular markers useful in practice for predicting prognosis of papillary thyroid carcinoma (PTC) despite numerous basic researches. The objective of this study was to evaluate the prognostic values of several candidate markers of PTC (p53, Ki-67 and galectin-3) using immunohistochemistry (IHC), one of the most practical methods. Methods: IHC for p53, Ki-67 and galectin-3 were performed on formalin-fixed paraffin-embedded tissues of 160 PTC specimens using monoclonal antibodies. The associations of the expressions of these markers with multiple clinicopathologic prognostic factors were assessed. Results: The overexpresion rates of p53, Ki-67 and galectin-3 were 48.8%, 64.3% and 97.8%, respectively. Overexpression of p53 protein was positively associated with extrathyroidal extension (P＜0.001). In addition, p53 immunoreactivity was more prevalent among Ki-67 overexpressed specimens (P＜0.001). Ki-67 immunoreactivity was positively correlated with tumor size (P＜0.05), which became more distinct when accompanied with p53 overexpression (P＜0.01). In contrast, no relationship between galectin-3 immunoreactivity and clinical prognostic factors was found. Conclusion: Our results suggest that overexpression of p53 protein and Ki-67 in papillary thyroid carcinoma is associated with tumor progression and that IHC for these proteins could be useful for predicting prognosis of patients with PTC.

키워드

참고문헌

  1. Ministry for Health, Welfare and Family Affairs. Annual Report of cancer incidence (2005) and survival (1993-2005) in Korea. 2008
  2. Ain KB. Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol Metab Clin North Am 1995;24:711- 60
  3. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28 https://doi.org/10.1016/0002-9343(94)90321-2
  4. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6 https://doi.org/10.1038/351453a0
  5. Farid NR. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Invest 2001;24:536-45 https://doi.org/10.1007/BF03343889
  6. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369-71
  7. Park SS, Huh JR, Lee SS, Kang YK, Heo DS, Kim CW. Correlation between clinical outcome and proliferation index in diffuse large B-cell lymphoma. Korean J Pathol 1999;33: 475-82
  8. Fukumori T, Kanayama HO, Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat 2007;10:101-8 https://doi.org/10.1016/j.drup.2007.04.001
  9. Yeo CJ. Tumor suppressor genes: a short review. Surgery 1999;125:363-6 https://doi.org/10.1016/S0039-6060(99)70001-2
  10. Dobosz T, Lukienczuk T, Sasiadek M, Kuczynska A, Jankowska E, Blin N. Microsatellite instability in thyroid papillary carcinoma and multinodular hyperplasia. Oncology 2000;58: 305-10 https://doi.org/10.1159/000012117
  11. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8 https://doi.org/10.1038/342705a0
  12. Nasir A, Catalano E, Calafati S, Cantor A, Kaiser HE, Coppola D. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. In Vivo 2004;18:189-95
  13. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18
  14. Park YK, Park HR, Chi SG, Ushigome S, Unni KK. Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma. Int J Oncol 2001;19:353-7
  15. Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 1994;47:337-9 https://doi.org/10.1136/jcp.47.4.337
  16. Chen BK, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Liang SB, et al. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol 1999;15:893-8
  17. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 1993;17:375-81 https://doi.org/10.1097/00000478-199304000-00008
  18. Godballe C, Asschenfeldt P, Jorgensen KE, Bastholt L, Clausen PP, Hansen TP, et al. Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. Laryngoscope 1998;108:243-9 https://doi.org/10.1097/00005537-199802000-00016
  19. Hosal SA, Apel RL, Freeman JL, Azadian A, Rosen IB, LiVolsi VA, et al. Immunohistochemical Localization of p53 in Human Thyroid Neoplasms: Correlation with Biological Behavior. Endocr Pathol 1997;8:21-8 https://doi.org/10.1007/BF02739704
  20. Holm R, Nesland JM. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 1994;172:267-72 https://doi.org/10.1002/path.1711720307
  21. Goldenberg JD, Portugal LG, Wenig BL, Ferrer K, Wu JC, Sabnani J. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density. Head Neck 1998;20:152-8 https://doi.org/10.1002/(SICI)1097-0347(199803)20:2<152::AID-HED9>3.0.CO;2-1
  22. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, et al. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. Thyroid 1996;6:1-9 https://doi.org/10.1089/thy.1996.6.1
  23. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17:489-503 https://doi.org/10.1111/j.1365-2559.1990.tb00788.x
  24. Hoos A, Lewis JJ, Antonescu CR, Dudas ME, Leon L, Woodruff JM, et al. Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype- phenotype association in soft tissue tumors. Cancer Res 2001;61:3171-5
  25. Hoos A, Stojadinovic A, Mastorides S, Urist MJ, Polsky D, Di Como CJ, et al. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 2001;92:869-74 https://doi.org/10.1002/1097-0142(20010815)92:4<869::AID-CNCR1395>3.0.CO;2-U
  26. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 1997;74:433-7 https://doi.org/10.1002/(SICI)1097-0215(19970822)74:4<433::AID-IJC12>3.0.CO;2-A
  27. Carr K, Heffess C, Jin L, Lloyd RV. Immunohistochemical analysis of the thyroid carcinoma initializing antibodies to p53 and Ki-67. Appl Immunohistochem 1993;1:201-7
  28. Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 2001;18: 787-92
  29. Kim JH, Han DH, Oh SJ, Rho YS, Ahn HY, Shin HS, et al. Clinical significance of the expression of galectin-3 in thyroid tumor. Korean J Otolaryngol - Head Neck Surg 2006;49:812-6

피인용 문헌

  1. Clinicopathological Characteristics of Colorectal Cancer according to Gender Difference vol.10, pp.4, 2009, https://doi.org/10.5217/ir.2012.10.4.365
  2. Clinicopathologic and Diagnostic Significance of p53 Protein Expression in Papillary Thyroid Carcinoma vol.15, pp.5, 2014, https://doi.org/10.7314/apjcp.2014.15.5.2341
  3. Prognostic Value of p53 and Cyclin D1 in Papillary Thyroid Carcinoma vol.15, pp.2, 2015, https://doi.org/10.16956/kjes.2015.15.2.25